IDH3α depletion promotes hypermethylation of cancer-relevant genes and reduces cancer progression, suggesting that targeting IDH3 or the interaction of cSHMT and IDH3α could hold therapeutic potential for glioblastoma (May et al. 2019). The gene discussed is IDH3A; the disease is glioblastoma.